Moreover, miR-205, together with miR-125b, inhibited HER3 expression and the activation of downstream signaling, decreasing cell proliferation and enhancing the G1 phase of cell cycle in a HER2 positive breast cancer model. Here, ERBB3 is linked to breast cancer.